Alamar Biosciences, Inc. (ALMR)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Loses money on what it sells.
- Revenue
- $74.2M
- Net income
- -$29.8M
- Net margin
- -40.2%
Not enough balance-sheet detail to judge the debt load.
- Total debt
- $41.5M
- Cash
- $30.0M
Comfortably covers what is due within a year.
- Current assets
- $94.7M
- Current liabilities
- $23.7M
- Current ratio
- 3.99
Consumes cash and must keep raising it.
- Operating cash flow
- -$53.6M
- Free cash flow
- -$60.0M
- FCF margin
- -80.8%
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 66.5M
- Share growth (1y)
- —
- Cash runway
- 7 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ALMR Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 |
|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 |
| Revenue | 29.43 M | 26.04 M |
| Revenue Growth (YoY) | — | — |
| Cost of Revenue | 11.71 M | 11.58 M |
| Gross Profit | 17.72 M | 14.46 M |
| SG&A Expense | 17.43 M | 13.79 M |
| R&D Expense | 13.82 M | 13.02 M |
| Operating Expenses | 31.25 M | 26.80 M |
| Operating Income | -13.53 M | -12.35 M |
| Pretax Income | -13.29 M | -20.86 M |
| Tax Provision | -93.00 K | 464.00 K |
| Net Income | -13.20 M | -21.32 M |
| EPS (Basic) | -0.22 | -0.31 |
| EPS (Diluted) | -0.22 | -0.31 |
| Shares Outstanding | 58.67 M | 69.31 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.